UroGen Pharma Ltd. Logo

UroGen Pharma Ltd.

Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.

URGN | US

Overview

Corporate Details

ISIN(s):
IL0011407140
LEI:
Country:
United States of America
Address:
9 HA'TA'ASIYA ST, 4365007 RA'ANANA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

UroGen Pharma Ltd. is a biotechnology company dedicated to developing and commercializing innovative solutions for urothelial and other specialty cancers. The company focuses on creating transformative, non-surgical therapies for urological diseases. Its lead commercial product, ZUSDURI™, is an FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGen utilizes its proprietary RTGel™ reverse-thermal hydrogel technology to enable sustained local delivery of therapeutic agents, aiming to improve patient outcomes and revolutionize the treatment paradigm in uro-oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all UroGen Pharma Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for UroGen Pharma Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for UroGen Pharma Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF

Talk to a Data Expert

Have a question? We'll get back to you promptly.